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Background
Laboratory-identified (LabID) Clostridium difficile events are reported publically by the 
Centers for Disease Control and Prevention National Healthcare Safety Network as a patient 
safety metric that influences facility reputation and reimbursement.1In broad terms, each 
unique, positive C difficile test, taken after day 3 of hospital admission, constitutes a health 
care facility-onset C difficile infection (HO-CDI) LabID event. This metric does not 
incorporate chart review; therefore, it is less labor-intensive and potentially more objective, 
but influenced by test characteristics and behaviors.
Many microbiology laboratories in the United States use highly sensitive nucleic acid 
amplification tests to detect C difficile toxin A or B genes.2 A positive test performed on an 
asymptomatic patient may represent colonization prevalent in a hospitalized population.3 
Delayed testing of a symptomatic patient, beyond the third day of hospitalization, can lead 
to misclassification of community-onset infection as HO-CDI. Facility knowledge of what 
HO-CDI events represent, coupled with interventions to promote appropriate and timely 
diagnostic testing – known as diagnostic stewardship (D.S.) – can address these issues.
We elucidate the proportion of reportable HO-CDI LabID events at our institution that 
represent true HO-CDI versus asymptomatic C. difficile colonization due to inappropriate 
testing or community-onset CDI with delayed testing.
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Methods
This study was conducted at The Johns Hopkins Hospital, a 1,145-bed tertiary academic 
center in Baltimore, Maryland. Trained infection preventionists conducted prospective chart 
review for each HO-CDI lab ID event from January 2015 to June 2016. “True HO-CDI” was 
defined as clinically significant diarrhea (≥3 episodes in 24 hours) not present on admission, 
without laxatives administered in the preceding 48 hours. A second retrospective chart 
review was later conducted for “non-true HO-CDI” cases to verify reasons and to ascertain 
treatment of CDI (metronidazole or vancomycin) within 14 days of positive test. New 
Standardized Infection Ratios (SIRs) including only “true HO-CDI” in the numerator were 
calculated for each quarter, and compared with the publically reported HO-CDI SIR.4
A prioritization matrix was used to rank services according to potential “return on 
performance improvement investment” to direct future diagnostic stewardship interventions. 
A service which is not contributing many events to the HO-CDI, or a service where tests are 
mostly appropriate, would likely not be a top priority for intervention. Prioritization matrices 
are used in other healthcare domains such as lean sigma and clinical decision support for 
breast care.5 Ranking of raw number of HO-CDI lab ID events (service contribution to the 
HO-CDI) was multiplied by ranking of percent inappropriate tests (a large proportion of 
inappropriate tests indicating significant opportunity for improvement). See table 1.
Results
There were 490 HO-CDI LabID events during 452,587 patient days; 284 (58%) were “true 
HO-CDI” whereas 206 (42%) were classified “non-true”: either inappropriate or delayed 
testing. Reasons for “non-true HO-CDI” included no significant diarrhea (94; 49.5%), 
laxative within previous 48 hours (78; 41%), and delayed testing (18; 9.5%). There were 16 
(7.8%) charts, where retrospective chart review to ascertain specific reason for “non-true 
HO-CDI” was not possible. Of 172 patients with inappropriate testing, 159 (92%) were 
treated for CDI. For the “true HO-CDI” every quarter SIR was below 1, compared with 2 of 
6 quarters for the publically reported HO-CDI. See figures 1a and 1b.
Discussion
We found that almost half of HO-CDI LabID events at our institution were not true 
healthcare facility-onset infections, but due to inappropriate or delayed testing. We recognize 
that HO-CDI LabID is a proxy for hospital-acquired infections, however, a discrepancy of 
this proportion is likely not consistent with the intent of the metric. We found “true HO-
CDI” SIRs were substantially lower than the publically reported SIRs, demonstrating how 
decreasing inappropriate testing could have an impact on a facility’s HO-CDI SIR and on 
reported rates of HO-CDI. Another major finding of this study is that over 90% of patients 
with inappropriate testing and apparent C. difficile colonization were treated for CDI. This 
unnecessary antibiotic treatment places these patients at risk for disruption of the intestinal 
microbiome, other adverse events or progression to CDI5.
Diagnostic stewardship interventions can be applied to C. difficile testing to ensure more 
appropriate testing. D.S. is an essential part of antibiotic stewardship, infection prevention, 
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and therapeutic decision-making.6,7 Potential DS approaches for C. difficile testing include 
education and electronic medical record best practice alerts to help clinicians avoid ordering 
a test when patient has had a recent laxative, or does not have clinically significant diarrhea, 
thereby increasing the pre-test probability of detecting only true C. difficile disease. In this 
study, the prioritization matrix approach identified medicine as a top priority for reduction in 
inappropriate or delayed testing. Interestingly, psychiatry was the second priority: although 
it did not contribute many HO-CDI LabIDs, a large proportion represented inappropriate or 
delayed testing, and therefore could have a significant yield from minimal diagnostic 
stewardship intervention or good “return on performance improvement investment”.
Revision of the HO-CDI LabID metric to include clinical data from chart review would 
likely increase specificity and more accurately measure true healthcare facility-onset C. 
difficile infection. Enhanced NHSN LabID risk adjustment for test method (NAAT, EIA, all 
others) might help account for increased sensitivity of NAAT. 8 Additional changes to the 
metric would be required if facilities were to adopt screening and use of contact precautions 
for asymptomatic C. difficile colonized patients.9 In the absence of changes to the metric, 
inflation of the reported HO-CDI could become even more pronounced.
This study has limitations. It was conducted at one academic center and may not be 
generalizable to other settings. Charts were not available for retrospective review of 7.7% of 
“non-true HO-CDI” cases to determine the reason; however, it is unlikely that a specific 
category was systematically excluded. We did not include lack of diarrhea due to paralytic 
ileus in the HO-CDI definition. However, the simple definition used was conservative and 
more likely to classify inappropriate tests as appropriate rather than vice versa.
Facilities and jurisdictions seeking to improve reported HO-CDI LabID should investigate 
what proportion of these HO-CDI LabID events represent true infections and what 
proportion represent delayed tests or inappropriate tests of asymptomatic, colonized patients. 
This information will allow for focused improvement efforts that are appropriately targeted; 
infection prevention and antimicrobial stewardship interventions to prevent true C. difficile 
acquisition in the healthcare setting, and diagnostic stewardship interventions to decrease 
inappropriate and delayed C. difficile testing.
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Figure 1a: 
True HO-CDI Rate vs NHSN LabID HO-CDI Rate
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Figure 1b: 
True HO-CDI SIR vs NHSN LabID HO- CDI Event SIR
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Table 1.
The prioritization matrix identified Medicine as having greatest potential benefit from diagnostic stewardship 
efforts, followed by Psychiatry and Surgery (Table).
Service
A. # HO-
CDI Lab ID
events
B. Rank
based on
HO-CDI
Lab ID
events
C. % HO-CDI
inappropriate
or delayed C.
diff tests
D. Rank based
on % HO-CDI
inappropriate
or delayed C.
diff tests
Prioritization
Score (B
multiplied
by D)
Prioritization
ranking
Medicine 160 2 62% 2 4 1
Psychiatry 6 6 67% 1 6 2
Surgery 181 1 23% 8 8 3
Pediatrics 30 5 43% 4 20 4
Neuro-Sciences 42 4 36% 5 20 4
Oncology 66 3 24% 7 21 5
Physical medicine rehabilitation 2 8 50% 3 24 6
OB/GYN 4 7 25% 6 42 7
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